A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Lapatinib (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 22 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top